

Kelderman Kim
 Form 4
 May 02, 2019

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Kelderman Kim

(Last) (First) (Middle)
 614 MCKINLEY PLACE NE
 (Street)

MINNEAPOLIS, MN 55413

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [TECH]

3. Date of Earliest Transaction (Month/Day/Year)
 05/01/2019

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

____ Director _____ 10% Owner
 ____ Officer (give title below) _____ Other (specify below)
 President, Diagnostics & Genom

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)
				(A) or (D) Code V Amount (D) Price			
Common Stock	05/01/2019		M	1,667 A \$ 202.13	1,667	D	
Common Stock	05/01/2019		F	844 D \$ 202.13	823	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Edgar Filing: Kelderman Kim - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock	\$ 0	05/01/2019		M	1,667	05/01/2019	05/01/2025	Common Stock	1,667
Restricted Stock Units	<u>(1)</u>					<u>(2)</u>	05/01/2025	Common Stock	3,333
Restricted Stock Units	<u>(1)</u>					<u>(3)</u>	<u>(3)</u>	Common Stock	1,691
Stock Options (Right to buy)	\$ 177.32					<u>(4)</u>	08/08/2025	Common Stock	12,044
Stock Options (Right to buy)	\$ 177.32					<u>(3)</u>	08/08/2025	Common Stock	9,033
Stock Options (Right to buy)	\$ 150.78					<u>(5)</u>	05/01/2025	Common Stock	2,652
Stock Options (Right to buy)	\$ 150.78					<u>(6)</u>	05/01/2025	Common Stock	7,348

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Kelderman Kim 614 MCKINLEY PLACE NE			President, Diagnostics &	

MINNEAPOLIS, MN 55413

Genom

Signatures

/s/ Brenda S. Furlow, attorney in fact for Kelderman, Kim pursuant to Power of Attorney
previously filed

05/02/2019

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
 - (2) Vests 1,666 shares each on 5/1/2020 and 1,667 shares on 5/1/2021
 - (3) Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
 - (4) 3,011 shares vest on each of 8/8/2019, 8/8/2020, 8/8/2021 and 8/8/2022
 - (5) 663 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022
 - (6) 1,837 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.